Synthetic double-stranded RNA poly(I:C) as a potent peptide vaccine adjuvant: therapeutic activity against human cervical cancer in a rodent model (original) (raw)
Buteau C, Markovic SN, Celis E (2002) Challenges in the development of effective peptide vaccines for cancer. Mayo Clin Proc 77(4):339–349 ArticlePubMedCAS Google Scholar
Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM (1996) CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci USA 93:2879–2883 ArticlePubMedCAS Google Scholar
Davila E, Kennedy R, Celis E (2003) Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res 63(12):3281–3288 PubMedCAS Google Scholar
Davila E, Celis E (2000) Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. J Immunol 165(1):539–547 PubMedCAS Google Scholar
Miconnet I, Koenig S, Speiser D et al. (2002) CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. J Immunol 168(3):1212–1218 PubMedCAS Google Scholar
Speiser DE, Lienard D, Rufer N et al. (2005) Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115(3):739–746 ArticlePubMedCAS Google Scholar
Kadowaki N, Ho S, Antonenko S et al. (2001) Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 194:863–869 ArticlePubMedCAS Google Scholar
Ulevitch RJ (2004) Therapeutics targeting the innate immune system. Nat Rev Immunol 4(7):512–520 ArticlePubMedCAS Google Scholar
Alexopoulou L, Holt AC, Medzhitov R, Flavell RA (2001) Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413:732–738 ArticlePubMedCAS Google Scholar
Herman R, Baron S (1971) Immunologic-mediated protection of _Trypanosoma congolense_-infected mice by polyribonucleotides. J Protozool 18(4):661–666 PubMedCAS Google Scholar
Park JH, Baron S (1968) Herpetic keratoconjunctivitis: therapy with synthetic double-stranded RNA. Science 162(855):811–813 ArticlePubMedCAS Google Scholar
Partidos CD, Hoebeke J, Moreau E et al. (2005) The binding affinity of double-stranded RNA motifs to HIV-1 Tat protein affects transactivation and the neutralizing capacity of anti-Tat antibodies elicited after intranasal immunization. Eur J Immunol 35(5):1521–1529 ArticlePubMedCAS Google Scholar
Ichinohe T, Watanabe I, Ito S et al. (2005) Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J Virol 79(5):2910–2919 ArticlePubMedCAS Google Scholar
Fujimoto C, Nakagawa Y, Ohara K, Takahashi H (2004) Polyriboinosinic polyribocytidylic acid [poly(I:C)]/TLR3 signaling allows class I processing of exogenous protein and induction of HIV-specific CD8+ cytotoxic T lymphocytes. Int Immunol 16(1):55–63 ArticlePubMedCAS Google Scholar
Meier WA, Husmann RJ, Schnitzlein WM, Osorio FA, Lunney JK, Zuckermann FA (2004) Cytokines and synthetic double-stranded RNA augment the T helper 1 immune response of swine to porcine reproductive and respiratory syndrome virus. Vet Immunol Immunopathol 102(3):299–314 ArticlePubMedCAS Google Scholar
Verdijk RM, Mutis T, Esendam B et al. (1999) Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells. J Immunol 163(1):57–61 PubMedCAS Google Scholar
Schmidt KN, Leung B, Kwong M et al. (2004) APC-independent activation of NK cells by the Toll-like receptor 3 agonist double-stranded RNA. J Immunol 172(1):138–143 PubMedCAS Google Scholar
Sivori S, Falco M, Della Chiesa M et al. (2004) CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proc Natl Acad Sci USA 101(27):10116–10121 ArticlePubMedCAS Google Scholar
Gelman AE, Zhang J, Choi Y, Turka LA (2004) Toll-like receptor ligands directly promote activated CD4+ T cell survival. J Immunol 172(10):6065–6073 PubMedCAS Google Scholar
Salem ML, Kadima AN, Cole DJ, Gillanders WE (2005) Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. J Immunother 28(3):220–228 ArticlePubMedCAS Google Scholar
Schulz O, Diebold SS, Chen M et al. (2005) Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433(7028):887–892 ArticlePubMedCAS Google Scholar
Franco EL, Schlecht NF, Saslow D (2003) The epidemiology of cervical cancer. Cancer J 9(5):348–359 ArticlePubMed Google Scholar
Munoz N, Bosch FX, de Sanjose S et al. (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348(6):518–527 ArticlePubMed Google Scholar
Scheffner M, Huibregtse JM, Vierstra RD, Howley PM (1993) The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495–505 ArticlePubMedCAS Google Scholar
Munger K, Scheffner M, Huibregtse JM, Howley PM (1992) Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products. Cancer Surv 12:197–217 PubMedCAS Google Scholar
Borysiewicz LK, Fiander A, Nimako M et al. (1996) A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347:1523–1527 ArticlePubMedCAS Google Scholar
Kaufmann AM, Stern PL, Rankin EM et al. (2002) Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res 8:3676–3685 PubMedCAS Google Scholar
Ferrara A, Nonn M, Sehr P et al. (2003) Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J Cancer Res Clin Oncol 129:521–530 ArticlePubMedCAS Google Scholar
Muderspach L, Wilczynski S, Roman L et al. (2000) A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 6:3406–3416 PubMedCAS Google Scholar
Steller MA, Gurski KJ, Murakami M et al. (1998) Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res 4(9):2103–2109 PubMedCAS Google Scholar
van Driel WJ, Ressing ME, Kenter GG et al. (1999) Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer 35(6):946–952 ArticlePubMed Google Scholar
Lin CW, Lee JY, Tsao YP, Shen CP, Lai HC, Chen SL (2002) Oral vaccination with recombinant Listeria monocytogenes expressing human papillomavirus type 16 E7 can cause tumor growth in mice to regress. Int J Cancer 102(6):629–637 ArticlePubMedCAS Google Scholar
Hwu P, Yang JC, Cowherd R et al. (1995) In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 55(15):3369–3373 PubMedCAS Google Scholar
Cui Z, Han SJ, Huang L (2004) Coating of mannan on LPD particles containing HPV E7 peptide significantly enhances immunity against HPV-positive tumor. Pharm Res 21:1018–1025 ArticlePubMedCAS Google Scholar
Cui Z, Huang L (2005) Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: Therapeutic effect against cervical cancer. Cancer Immunol Immunother 54(12):1180–1190 ArticlePubMedCAS Google Scholar
Dileo J, Banerjee R, Whitmore M, Nayak JV, Falo LD Jr, Huang L (2003) Lipid-protamine-DNA-mediated antigen delivery to antigen-presenting cells results in enhanced anti-tumor immune responses. Mol Ther 7:640–648 ArticlePubMedCAS Google Scholar
Curtsinger JM, Johnson CM, Mescher MF (2003) CD8 T cell clonal expansion and development of effector function require prolonged exposure to antigen, costimulation, and signal 3 cytokine. J Immunol 171(10):5165–5171 PubMedCAS Google Scholar
den Boer AT, van Mierlo GJ, Fransen MF, Melief CJ, Offringa R, Toes RE (2004) The tumoricidal activity of memory CD8+ T cells is hampered by persistent systemic antigen, but full functional capacity is regained in an antigen-free environment. J Immunol 172(10):6074–6079 PubMed Google Scholar
Toes RE, Offringa R, Blom RJ, Melief CJ, Kast WM (1996) Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci USA 93(15):7855–7860 ArticlePubMedCAS Google Scholar
Hoerr I, Obst R, Rammensee HG, Jung G (2000) In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol 30(1):1–7 ArticlePubMedCAS Google Scholar
Blattman JN, Greenberg PD (2004) Cancer immunotherapy: a treatment for the masses. Science 305(5681):200–205 ArticlePubMedCAS Google Scholar
Berzofsky JA, Ahlers JD, Janik J et al. (2004) Progress on new vaccine strategies against chronic viral infections. J Clin Invest 114(4):450–462 ArticlePubMedCAS Google Scholar
Walboomers JM, Jacobs MV, Manos MM et al. (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189(1):12–19 ArticlePubMedCAS Google Scholar
Ong MK, Glantz SA (2004) Cardiovascular health and economic effects of smoke-free workplaces. Am J Med 117(1):32–38 ArticlePubMed Google Scholar
Franceschi S (2005) The IARC commitment to cancer prevention: the example of papillomavirus and cervical cancer. Recent Results Cancer Res 166:277–297 PubMed Google Scholar
Kadish AS, Timmins P, Wang Y et al. (2002) Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide. Cancer Epidemiol Biomarkers Prev 11:483–488 PubMedCAS Google Scholar
Hirabayashi K, Yano J, Inoue T et al. (1999) Inhibition of cancer cell growth by polyinosinic-polycytidylic acid/cationic liposome complex: a new biological activity. Cancer Res 59(17):4325–4333 PubMedCAS Google Scholar
Hemmi H, Takeuchi O, Kawai T et al. (2000) A Toll-like receptor recognizes bacterial DNA. Nature 408(6813):740–745 ArticlePubMedCAS Google Scholar
Krieg AM, Yi AK, Matson S et al. (1995) CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374(6522):546–549 ArticlePubMedCAS Google Scholar
Jacobs BL, Langland JO (1996) When two strands are better than one: the mediators and modulators of the cellular responses to double-stranded RNA. Virology 219(2):339–349 ArticlePubMedCAS Google Scholar
Lindh HF, Lindsay HL, Mayberry BR, Forbes M (1969) Polyinosinic-cytidylic acid complex (poly I:C) and viral infections in mice. Proc Soc Exp Biol Med 132(1):83–87 PubMedCAS Google Scholar
Tabeta K, Georgel P, Janssen E et al. (2004) Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc Natl Acad Sci USA 101(10):3516–3521 ArticlePubMedCAS Google Scholar
Yang L, Carbone DP (2004) Tumor-host immune interactions and dendritic cell dysfunction. Adv Cancer Res 92:13–27 ArticlePubMedCAS Google Scholar
Almand B, Resser JR, Lindman B et al. (2000) Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 6(5):1755–1766 PubMedCAS Google Scholar
Gabrilovich DI, Chen HL, Girgis KR et al (1996) Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2(10):1096–1103 ArticlePubMedCAS Google Scholar
Morelli AE, Larregina AT, Ganster RW et al. (2000) Recombinant adenovirus induces maturation of dendritic cells via an NF-kappaB-dependent pathway. J Virol 74(20):9617–9628 ArticlePubMedCAS Google Scholar
Muraille E, De Trez C, Pajak B, Torentera FA, De Baetselier P, Leo O, Carlier Y (2003) Amastigote load and cell surface phenotype of infected cells from lesions and lymph nodes of susceptible and resistant mice infected with Leishmania major. Infect Immun 71(5):2704–2715 ArticlePubMedCAS Google Scholar
Coates PT, Barratt-Boyes SM, Zhang L et al. (2003) Dendritic cell subsets in blood and lymphoid tissue of rhesus monkeys and their mobilization with Flt3 ligand. Blood 102(7):2513–2521 ArticlePubMedCAS Google Scholar
Fischer HG, Bonifas U, Reichmann G (2000) Phenotype and functions of brain dendritic cells emerging during chronic infection of mice with Toxoplasma gondii. J Immunol 164(9):4826–4834 PubMedCAS Google Scholar
Nishi T, Okazaki K, Kawasaki K et al. (2003) Involvement of myeloid dendritic cells in the development of gastric secondary lymphoid follicles in _Helicobacter pylori_-infected neonatally thymectomized BALB/c mice. Infect Immun 71(4):2153–2162 ArticlePubMedCAS Google Scholar
Blois SM, Alba Soto CD, Tometten M, Klapp BF, Margni RA, Arck PC (2004) Lineage, maturity, and phenotype of uterine murine dendritic cells throughout gestation indicate a protective role in maintaining pregnancy. Biol Reprod 70(4):1018–1023 ArticlePubMedCAS Google Scholar
Turner BC, Hemmila EM, Beauchemin N, Holmes KV (2004) Receptor-dependent coronavirus infection of dendritic cells. J Virol 78(10):5486–5490 ArticlePubMedCAS Google Scholar
Schiavoni G, Mattei F, Sestili P et al. (2002) ICSBP is essential for the development of mouse type I interferon-producing cells and for the generation and activation of CD8alpha(+) dendritic cells. J Exp Med 196(11):1415–1425 ArticlePubMedCAS Google Scholar
Kruger T, Benke D, Eitner F et al. (2004) Identification and functional characterization of dendritic cells in the healthy murine kidney and in experimental glomerulonephritis. J Am Soc Nephrol 15(3):613–621 ArticlePubMed Google Scholar
Kadowaki N, Antonenko S, Liu YJ (2001) Distinct CpG DNA and polyinosinic-polycytidylic acid double-stranded RNA, respectively, stimulate CD11c- type 2 dendritic cell precursors and CD11c+ dendritic cells to produce type I IFN. J Immunol 166(4):2291–2295 PubMedCAS Google Scholar
Strayer DR, Carter WA, Brodsky I et al. (1994) A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome. Clin Infect Dis 18(Suppl 1):S88–95 PubMed Google Scholar
Adams M, Navabi H, Jasani B et al. (2003) Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen R). Vaccine 21(7–8):787–790 ArticlePubMedCAS Google Scholar
Fernando GJ, Khammanivong V, Leggatt GR, Liu WJ, Frazer IH (2002) The number of long-lasting functional memory CD8+ T cells generated depends on the nature of the initial nonspecific stimulation. Eur J Immunol 32(6):1541–1549 ArticlePubMedCAS Google Scholar